Tech Company Financing Transactions
Epic Bio Funding Round
On 7/12/2022, Epic Bio raised $55 million in Series A investment from private investors.
Transaction Overview
Company Name
Announced On
7/12/2022
Transaction Type
Venture Equity
Amount
$55,000,000
Round
Series A
Investors
Proceeds Purpose
The Series A will support Epic's preclinical programs in five initial indications that are insufficiently addressed by today's genetic medicines -- Facioscapulohumeral Muscular Dystrophy (FSHD), Heterozygous Familial Hypercholesterolemia (HeFH), Alpha-1 Antitrypsin Deficiency (A1AD), Retinitis Pigmentosa 4 (RP4), and Retinitis Pigmentosa 11 (RP11) -- as well as the ongoing development of the company's platform and discovery efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7000 Shoreline Ct. 100
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Epic Bio is building the world's leading therapeutic platform based on the exciting new technology of epigenetic engineering. We were founded by genetic medicine pioneer Stanley Qi, Ph.D., whose fundamental work in epigenetic engineering includes the invention of CRISPRa (activation) and CRISPRi (interference).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Amber Salzman
Chief Operating Officer
Benson Cheng
Chief Technical Officer
Daniel Hart
Browse more venture capital transactions:
Prev: 7/12/2022: SiTration venture capital transaction
Next: 7/12/2022: Pattern Brands venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs